# IO Biotech

Source: https://onco.cc/companies/io-biotech/  
OnCo record `io-biotech` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

IO Biotech makes an off-the-shelf cancer vaccine that trains T cells to attack both tumour cells and the immune-suppressing cells around them. Its large melanoma trial narrowly missed its main goal in 2025 and the company is now reviewing its options.

## Summary

IO Biotech (Nasdaq: IOBT), headquartered in Copenhagen with a US office in New York, develops immune-modulatory cancer vaccines on its T-win platform. Lead candidate Cylembio (IO102-IO103) stimulates T cells against indoleamine 2,3-dioxygenase 1 (IDO1) positive and PD-L1 positive cells, aiming to kill both tumour cells and immune-suppressive cells in the tumour microenvironment. In the phase 3 IOB-013 trial in first-line advanced melanoma, Cylembio plus pembrolizumab gave median progression-free survival of 19.4 months versus 11.0 months for pembrolizumab alone (hazard ratio 0.77, 95 percent CI 0.58 to 1.00, p=0.0558), narrowly missing the prespecified significance threshold of p≤0.045 (ESMO, October 2025). Five-year outcomes from the phase 1/2 trial were published in Nature Communications in December 2025. In January 2026 the company engaged Raymond James to explore strategic alternatives and announced a workforce reduction to preserve cash.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Copenhagen
- Type: biotech
- Website: https://www.iobiotech.com
- Ticker: IOBT

## Notes

- No financing round could be sourced from fetched pages. Outcome of the strategic review after January 2026 not verified. Founding year not sourced.

## Sources

- Official website: https://www.iobiotech.com
- Phase 3 results for Cylembio plus pembrolizumab (ESMO 2025): https://www.globenewswire.com/news-release/2025/10/20/3169094/0/en/io-biotech-presents-phase-3-results-for-cylembio-plus-keytruda-pembrolizumab-in-first-line-advanced-melanoma-at-esmo-2025.html
- Corporate update and strategic alternatives (January 2026): https://www.globenewswire.com/news-release/2026/01/30/3229500/0/en/io-biotech-provides-corporate-update.html

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/)
- targets: [PD-L1](https://onco.cc/targets/pdl1/)
- drugs: [IO102-IO103](https://onco.cc/drugs/io102-io103/)
- trials: [IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)](https://onco.cc/trials/nct05155254/), [Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors](https://onco.cc/trials/nct05280314/)

---
JSON: https://onco.cc/api/v1/entities/io-biotech.json